Thursday, May 28, 2020 | Last Update : 02:11 PM IST

64th Day Of Lockdown

Maharashtra54758169541792 Tamil Nadu177289342128 Delhi152577264303 Gujarat148297139915 Rajasthan76804341172 Madhya Pradesh70243689305 Uttar Pradesh67243824177 West Bengal40091486283 Andhra Pradesh3117206558 Bihar300680014 Karnataka240576245 Punjab2106191840 Telangana1991128457 Jammu and Kashmir175983324 Odisha15937337 Haryana130582416 Kerala9645426 Assam683634 Jharkhand4261534 Uttarakhand400644 Chhatisgarh360790 Chandigarh2781874 Tripura2321650 Himachal Pradesh223634 Goa67280 Puducherry49170 Manipur3940 Meghalaya20121 Nagaland900 Arunachal Pradesh210 Mizoram110 Sikkim100

Indian firm to test Covid vaccine in 3 weeks; if successful, drug won't be patented

THE ASIAN AGE. | ASIAN AGE WEB DESK
Published : Apr 26, 2020, 1:55 pm IST
Updated : Apr 26, 2020, 1:55 pm IST

If human clinical trials are successful, product will be out in the market by October

Pune's Serum Institute of India's Covid vaccine to be out in the market by October, but only if human trials are successful . (Photo: Serum Institute of India)
 Pune's Serum Institute of India's Covid vaccine to be out in the market by October, but only if human trials are successful . (Photo: Serum Institute of India)

New Delhi: Indian vaccine major Serum Institute of India said on Sunday that it plans to start production of the COVID-19 vaccine developed by Oxford University in the next two to three weeks.

If human clinical trials of the vacine are successful, the product should be available in the market by October.

However, human clinical trials are a big if. They will take place in the UK.

The Pune-based company has partnered with Oxford University as one of the seven global institutions manufacturing the vaccine.

"Our team has been working closely with Dr Hill from Oxford University, and we are expecting to initiate production of the vaccine in 2-3 weeks and produce 5 million doses per month for the first six months, following which we hope to scale up production to 10 million doses per month," Serum Institute India (SII) CEO Adar Poonawalla said.

SII has collaborated with scientists at Oxford University for a malaria vaccine project in the past and can say with certainty that they are some of the best scientists, he added.

"We expect the (COVID-19) vaccine to be out in the market by September-October, only if the trials are successful with the requisite safety and assured efficacy. We will be starting trials in India for this vaccine hopefully over the next 2-3 weeks' time," Poonawalla said.

SII will begin manufacturing the vaccine in anticipation of clinical trials succeeding by September-October in the UK, he added.

"Following that, we have undertaken the decision to initiate manufacturing at our own risk. The decision has been solely taken to have a jump-start on manufacturing, to have enough doses available, if the clinical trials prove successful," Poonawalla said.

The company plans to initiate the trials in India for the vaccine with necessary regulatory approvals, which are underway presently.

"Keeping the current situation in mind, we have funded this endeavour at a personal capacity and hopefully will be able to enlist the support of other partners to further scale-up vaccine production," Poonawalla said.

The vaccines will be manufactured at the company's facility in Pune. Building a new facility for COVID-19 vaccine would have taken around  2-3 years, he added.

Indian regulatory authorities are working with the company to ensure smooth procedural functioning. "We are in touch with the Department of Biotechnology (DBT) and ICMR," Poonawalla said.

The company had earlier said it will not patent any COVID-19 vaccine which it develops.

Asked about the decision, Poonawalla reiterated, "We will not patent Serum's vaccine for COVID-19 and will make it available for all to produce and sell, not just in India but across the world."

Whosoever makes and develops the vaccine will need multiple partners to manufacture the vaccine, he added.

"I hope that whichever company develops the vaccine does not get it patented and makes it available based on royalties or a commercial understanding to as many manufacturers across the world to make billions of dosages at a fast pace," Poonawalla said.

Death toll due to COVID-19 has crossed 200,000 globally, with the number of infections at over 2.8 million.

In India, the coronavirus has claimed over 800 lives and the number of cases has crossed the 26,000-mark.

Tags: sii, serum institute of india, covid-19 vaccine, oxford university
Location: India, Maharashtra, Pune